HCB101 binds CD47 on tumor cells to block the CD47–SIRPα checkpoint, enabling macrophage-mediated phagocytosis; its IgG4 Fc engages Fcγ receptors (including CD32A) to enhance myeloid effector function, but CD32A-expressing cells are not targeted or killed.